Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.47 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 7/20 | 0.40 |
| ▸ | ERN1 | O75460 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20207166 | 1.00 | PAOX (0.47) | PAOXDDAH1TGM2EPHX2ACHE | |
| Hydrochloric Acid SCHEMBL2525927 | 0.98 | PAOX (0.46) | PAOXDDAH1TGM2EPHX2ACHE | |
| SCHEMBL1276392 | 0.98 | DDAH1 (0.46) | PAOXDDAH1TGM2EPHX2ACHE | |
| Hydrochloric Acid SCHEMBL28713623 | 0.97 | DDAH1 (0.45) | PAOXDDAH1TGM2EPHX2ACHE | |
| SCHEMBL28255342 | 0.93 | ACHE (0.40) | PAOXDDAH1TGM2EPHX2ACHE | |
| Hydrochloric Acid SCHEMBL28852389 | 0.91 | DDAH1 (0.39) | PAOXDDAH1TGM2EPHX2ACHE | |
| SCHEMBL3676772 | 0.91 | TGM2 (0.46) | TGM2EPHX2ACHEERN1EPHX1 | |
| SCHEMBL15109209 | 0.86 | ALDH1A1 (0.46) | TGM2EPHX2ACHEERN1EPHX1 | |
| SCHEMBL7001155 | 0.85 | MAPT (0.42) | TGM2ACHEERN1TSHRMAPT | |
| SCHEMBL991007 | 0.84 | ACHE (0.51) | TGM2EPHX2ACHEERN1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6646129-B2 | Treatment of psoriasis and skin cancer | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2003-11-11 | — | — | US | disclosed |
| EP-0984936-B1 | CYANOGUANIDINES AS CELL PROLIFERATION INHIBITORS | LEO PHARMA AS WITH SECONDARY N (DK) | 2003-09-03 | — | — | EP | disclosed |
| US-20020107400-A1 | Cyanoguanidines as cell proliferation inhibitors | LEO PHARMACEUTICAL PRODUCTS LTD. A/S | 2002-08-08 | — | — | US | disclosed |
| US-6346520-B1 | ANTITUMOR AND ANTICARCINOGENIC AGENTS; PSORIASIS | LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) | 2002-02-12 | — | — | US | disclosed |
| EP-0984936-A1 | CYANOGUANIDINES AS CELL PROLIFERATION INHIBITORS | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998054141-A1 | CYANOGUANIDINES AS CELL PROLIFERATION INHIBITORS | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107400-A1 | Cyanoguanidines as cell proliferation inhibitors | CCNC, MKI67, CCNI | PAOX 741/4885DDAH1 162/4885TGM2 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.